Clinical Trial Detail

NCT ID NCT01303341
Title Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

Advanced Solid Tumor

melanoma

Therapies

Riluzole + Sorafenib

Age Groups: adult senior

No variant requirements are available.